AACI/SIRUM Webinar | Leveraging Oncology Surplus Medicine for Good
New date and time! Monday, August 10, 1:00 pm ET
Every year in the United States, $11 billion worth of perfectly good, unopened medicine goes to waste. A surplus of $2 billion comes directly from oncology, yet the majority of cancer patients struggle with their high prescription costs. There are programs across the country that work to facilitate the donation and reuse of this surplus through repositories and charitable pharmacies. SIRUM—a national drug donation expert—works with policymakers, drug repository programs, and cancer centers to help facilitate this redistribution. To date, SIRUM has redistributed more than $350 million worth of prescription medications.
Presenters: George Wang, PhD, SIRUM; Heather Jones, PharmD, MS, Cleveland Clinic; Jennifer Booth, PharmD, MS, BCPS, The Ohio State University Wexner Medical Center
Webinars are hosted on the Medlive platform and open to all AACI members. Registration is free with the creation of a Medlive account. Please contact AACI Program Manager Hailey Honeycutt with any questions.
AACI Update | July 2026
Headlines
Gius Takes Helm as Director of University of Cincinnati Cancer Center
Following a national search, David Gius, MD, PhD, has assumed the role of director of the University of Cincinnati Cancer Center. Dr. Gius brings with him a nationally recognized research portfolio, including two National Institutes of Health R01 grants and two active clinical trials for women with high-risk breast cancer. He previously served as associate cancer center director at Mays Cancer Center at UT Health San Antonio MD Anderson.
AACI Welcomes Graham Cancer Center to Membership
AACI is pleased to add Helen F. Graham Cancer Center & Research Institute at ChristianaCare to its membership roster. Led by Bank of America Endowed Medical Director Thomas Schwaab, MD, PhD, the multidisciplinary cancer center serves most patients with cancer in Delaware. The Graham Cancer Center offers advanced medical, surgical, and radiation procedures and diagnostic services, including the ChristianaCare Breast Center, an outpatient facility featuring the only dedicated breast MRI in the region.
AACI Announces 2026 Award Recipients
Pictured, clockwise from top right: Dr. Rafi Ahmed, the Cattlemen's Ball of Nebraska, and Dr. Lucile Adams-Campbell
AACI congratulates this year's Distinguished Scientist, Cancer Health Equity, and Champion for Cures award recipients. The awards will be presented on Monday, October 26 during the 2026 AACI/CCAF Annual Meeting in Chicago.
AACI CRI Annual Meeting Recap: Shaping the Future of Clinical Research Innovation
Photo credit: Randy Belice
AACI hosted 18th Annual Clinical Research Innovation (CRI) Meeting, June 23-25, in Rosemont, IL. Focusing on "Shaping the Future of Clinical Research Innovation," the event drew over 600 registrants—including 613 in-person attendees—with 143 abstracts submitted for presentation.
New AACI White Paper Addresses Persistent Barriers in Clinical Trial Start-up
AACI is pleased to share Accelerating Clinical Trial Activation: A Collaborative Framework for Managing Pre-Activation Protocol Amendments. This new white paper from the AACI Corporate Roundtable Trial Activation Task Force builds on AACI’s ongoing efforts to improve oncology clinical trial activation through benchmarking, collaboration, and innovation across North American cancer centers.
AACI Calls for Reducing Waste in Clinical Trial Supply Kits
Last month, AACI published Sustainable Practices for Disposing of Unused Lab Kit Supplies in Cancer Clinical Trials. The AACI Clinical Research Innovation (CRI) Unused Lab Kit Supplies Task Force developed the call to action to address the significant volume of unused laboratory kits generated by industry-sponsored clinical trials. With reports indicating that up to 50 percent of trial laboratory kits go unused, cancer centers face increasing costs, storage burdens, staff workload, and environmental waste.
Upcoming Webinar: Leveraging Oncology Surplus Medicine for Good
Pictured, clockwise from top right: Drs. George Wang, Heather Jones, and Jennifer Booth
In partnership with SIRUM, AACI will host a webinar titled "Leveraging Oncology Surplus Medicine for Good" at 1:00 pm eastern time on Monday, August 10. Learn more about how surplus medicine can be safely and effectively donated with presenters George Wang, PhD, SIRUM; Heather Jones, PharmD, MS, Cleveland Clinic; and Jennifer Booth, PharmD, MS, BCPS, The Ohio State University Wexner Medical Center.
OMB Proposes Sweeping Changes to Federal Financial Assistance
AACI is submitting institutional comments on Regulation for Federal Financial Assistance (OMB-2026-0034), a proposed rule posted to the Federal Register on Friday, May 29 by the White House Office of Management and Budget (OMB). The comments were developed with input from cancer center leaders on provisions related to grant delivery, permissible research, and the use of grant funding that could significantly impact AACI members. AACI urges members to submit substantive, evidence-based comments that describe the specific impact of the proposed rule on you or your institution by Monday, July 13.
OVAC Congressional Briefing Highlights Importance of Federal Investment in Cancer Research
Pictured, left to right: Drs. Anthony Letai and Barry P. Sleckman
On Tuesday, June 23, AACI participated in a bipartisan congressional briefing on Capitol Hill, hosted by One Voice Against Cancer (OVAC). The briefing brought together congressional staff, advocacy partners, researchers, clinicians, and patients to highlight the impact of federally funded cancer research and the critical role of the National Cancer Institute in advancing progress against the disease.
News from the Centers
Zipfel Elected President of Society of Neurological Surgeons
Siteman Cancer Center
Gregory J. Zipfel, MD, the Ralph G. Dacey Distinguished Professor of Neurosurgery and head of the Taylor Family Department of Neurosurgery at WashU Medicine, and a research member of Siteman Cancer Center, has been elected president of the Society of Neurological Surgeons, the world's oldest neurological society.
Theodorescu Awarded Spence Medal
The University of Arizona Cancer Center
Dan Theodorescu, MD, PhD, the Nancy C. and Craig M. Berge Endowed Chair and director of the University of Arizona Comprehensive Cancer Center, has been awarded the Spence Medal by the American Association of Genitourinary Surgeons. The Spence Medal recognizes outstanding lifetime contributions to the field of urology through research, innovation, leadership, mentorship, and service.
Vander Heiden Named Editor-in-Chief of AACR Journal
Koch Institute for Integrative Cancer Research at MIT
The American Association for Cancer Research (AACR) has appointed Matthew Vander Heiden, MD, PhD, as editor-in-chief of Cancer Discovery, one of the 10 journals published by AACR. Dr. Vander Heiden is director of the Koch Institute for Integrative Cancer Research at MIT.
Desai Receives ASCO Career Development Award
Fox Chase Cancer Center, Temple Health
Parth Desai, MBBS, MD, assistant professor in the Fox Chase Department of Hematology/Oncology and director of clinical and translational research for the Thoracic and Head and Neck Service Lines, has received the ASCO Conquer Cancer Career Development Award. Dr. Desai's work focuses on converting "immune-cold" tumors—those that fail to attract or activate immune cells—into tumors that can respond to immunotherapy.
Radiation Therapy Team Recognized for Excellence by ASTRO
Siteman Cancer Center
The American Society for Radiation Oncology (ASTRO) has again recognized the Department of Radiation Oncology at Siteman Cancer Center and WashU Medicine as among the best in the nation. Sana Karam, MD, PhD, is chair of Radiation Oncology at Siteman Cancer Center.
Tewari Awarded Honorary Fellowship
Mount Sinai Tisch Cancer Center
Ashutosh Tewari, MBBS, director of the Center of Excellence for Prostate Cancer at Mount Sinai Tisch Cancer Center, was awarded an honorary fellowship by the Royal College of Physicians and Surgeons of Glasgow. Dr. Tewari was recognized as a pioneer of robotic surgery and for his work on genomic causes of prostate cancer and innovative imaging techniques to identify key biomarkers.
Roswell Park Recognized for Cancer Prevention and Early Detection Efforts
Roswell Park Comprehensive Cancer Center
Last month, U.S. Representatives Tim Kennedy (D-NY) and Jim McGovern (D-MA) and individuals representing the Prevent Cancer Foundation’s Congressional Families® Program and the Seneca Nation of Indians visited Roswell Park to recognize the cancer center's leadership in cancer prevention, screening, early detection, and community outreach. Candace S. Johnson, PhD, is president and CEO of the cancer center.
Kamber Named a 2026 Pew-Stewart Scholar
UCSF Helen Diller Family Comprehensive Cancer Center
Roarke Kamber, PhD, an assistant professor in the Department of Anatomy at UC San Francisco, has been named a 2026 Pew-Stewart Scholar, an award that supports early-career scientists who pursue breakthroughs in cancer development, diagnosis, and treatment. Dr. Kamber wants to retrain macrophages, the immune system’s garbage disposal cells, to destroy cancer.
St. Jude Redesignated as WHO Collaborating Centre for Childhood Cancer
Comprehensive Cancer Center St. Jude Children's Research Hospital
St. Jude Children’s Research Hospital has been redesignated as a World Health Organization (WHO) Collaborating Centre for Childhood Cancer, reaffirming the longstanding collaboration between WHO and St. Jude to improve outcomes for children with cancer worldwide through the provision of strategic, scientific, and technical expertise.
UChicago Renewed to Host NRG Oncology Statistics and Data Management Center for NCI
The University of Chicago Medicine Comprehensive Cancer Center
The University of Chicago has been awarded $66 million in renewal funding from the National Cancer Institute (NCI) to support the NRG Oncology Statistics and Data Management Center, which provides expertise in biostatistics, data management, and operational support for national clinical trials. NRG Oncology is a member of the NCI National Clinical Trials Network program, consisting of five network groups that conduct clinical trials across a spectrum of adult and pediatric cancers.
Moores Cancer Center Receives $25 Million in NCI Support
UC San Diego Moores Cancer Center
UC San Diego Moores Cancer Center has received a five-year, $25 million Cancer Center Support Grant from the National Cancer Institute (NCI). The award will sustain the cancer center’s mission to bring innovative discoveries into the clinic, increase access to cancer care, and train the next generation of cancer researchers. Diane M. Simeone, MD, is center director and a member of AACI's Board of Directors.
Funding Renewed for Biomedical Research Program
UAMS Winthrop P. Rockefeller Cancer Institute
A federal grant that funds the Arkansas Institutional Development Award (IDeA) Networks of Biomedical Research Excellence (INBRE) has been extended for another five years. The latest grant from the National Institute of General Medical Sciences, part of the National Institutes of Health (NIH), is for $19.6 million. INBRE is a statewide biomedical research program funded by the NIH and led by the University of Arkansas for Medical Sciences, that builds biomedical research capacity in states that historically receive lower levels of federal funding.
NCI Selects UChicago Medicine as Lead Site for Clinical Trials
The University of Chicago Medicine Comprehensive Cancer Center
The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) will remain one of the nation's leading sites for cancer clinical research, thanks to a new, six-year, $5 million grant from the National Cancer Institute (NCI). The funding, which comes from the NCI's UG1 National Clinical Trials Network (NCTN) grant program, supports UCCCC's continued participation as a Lead Academic Participating Site within the NCTN.
Adams Named Deputy Director of UNM Comprehensive Cancer Center
University of New Mexico Comprehensive Cancer Center
Sarah Adams, MD, has been appointed deputy director of the University of New Mexico (UNM) Comprehensive Cancer Center, effective July 1. Dr. Adams is a nationally recognized physician‑scientist whose research focuses on tumor immunology and novel immunotherapy strategies for ovarian cancer. She succeeds Alan Tomkinson, PhD, as deputy director.
Brenner to Lead New Houston Methodist Center for Cell and Gene Therapy
Houston Methodist Dr. Mary and Ron Neal Cancer Center
Malcolm Brenner, MD, PhD, has been tapped to lead the newly formed Houston Methodist Center for Cell and Gene Therapy. The center will foster interdisciplinary collaboration by bringing together scientists and clinicians across Houston Methodist to accelerate the translation of promising pre-clinical discoveries into clinical evaluation.
Sahin to Co-Lead Cancer Biology & Immunology Program
Hollings Cancer Center, Medical University of South Carolina
Ozgur Sahin, PhD, has joined Sophie Paczesny, MD, PhD, as co-leader of the Cancer Biology & Immunology Program at MUSC Hollings Cancer Center. Dr. Sahin currently serves as Hollings Advisory for Rapid Translation (HART) program director for basic science translation and co-leader of the Breast Transdisciplinary Cancer Team.
Figueiredo Appointed Associate Director for Population Sciences
Cedars-Sinai Cancer
Jane Figueiredo, PhD, professor of medicine, has been appointed as the new associate director for Population Sciences at Cedars-Sinai Cancer. Dr. Figueiredo, who joined Cedars-Sinai Cancer in 2016, also serves as the director for Community and Population Health Research and associate director for the Center for Integrated Research on Cancer and Lifestyle.
Rojewski Named Assistant Director, Clinical Trials & Healthcare Provider Training
Hollings Cancer Center, Medical University of South Carolina
Alana Rojewski, PhD, has been appointed assistant director, Clinical Trials & Healthcare Provider Training, in the MUSC Hollings Cancer Center Office of Cancer Research Training Education Coordination. Dr. Rojewski will spearhead training efforts across South Carolina, advancing education initiatives for staff, providers, and allied health professionals.
Novel Tool Optimizes Data Collection in Investigator-Initiated Clinical Trials
UF Health Cancer Institute
The UF Health Cancer Institute’s Clinical Research Office has developed and implemented a practical tool that supports data-driven, endpoint-focused clinical trial design. The work won first place in the abstract competition at the 18th Annual AACI Clinical Research (CRI) Innovation Meeting. Nina McGrew, MSN, RN, ACRP-CP, assistant director of project management and network operations, is first author of the abstract.
Bladder Cancer History May Predict Treatment Success
Duke Cancer Institute
New research from Duke Cancer Institute is helping uncover why some bladder cancer patients are less likely to benefit from a common treatment and how a patient’s cancer history may help guide more personalized care decisions in the future.
Magnetic Particle Imaging May Help Researchers Find More Effective Ways to Deliver Cell Therapies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Scientists at Johns Hopkins Medicine used a form of magnetic imaging to track cell therapy injections commonly used to treat certain autoimmune diseases and cancers. The findings add to a growing body of evidence that magnetic particle imaging, a new technique that allows scientists to visualize therapeutic cells as they inject them, may eventually help researchers personalize cell therapy treatments for individual patients. The National Institutes of Health-funded study was published in Science Advances.
Molecular 'Seesaw' Drives Healthy Skin Development
Stanford Cancer Institute
Two proteins with opposing functions orchestrate the development and maintenance of healthy skin, Stanford Medicine researchers have found. Modulating their activity with topical drugs could reduce inflammation, aid wound healing, and slow or halt the growth of skin cancer, the researchers believe.
Investigational Targeted Therapy Doubles Survival in Metastatic Pancreatic Cancer
UCLA Jonsson Comprehensive Cancer Center
Zev A. Wainberg, MD, professor of medicine and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, is co-first author of a study that showed an investigational targeted therapy significantly extended overall survival for patients with previously treated metastatic pancreatic cancer and reduced the risk of death by 60 percent compared with standard chemotherapy.
Study Shows Promise for New Targeted Combination in People With Relapsed AML
Roswell Park Comprehensive Cancer Center
New research co-led by Eunice Wang, MD, chief of leukemia at Roswell Park, highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form of acute myeloid leukemia (AML). The findings, published in the journal Blood, show encouraging results from a three-drug combination therapy in patients whose leukemia has returned or not responded to prior treatment.
Study Sheds Light on How Early Pancreas Lesions Become Cancerous
University of Michigan Rogel Cancer Center
Rogel Cancer Center researchers unexpectedly discovered that the microenvironment of precursor lesions that may evolve into pancreatic cancer is the same as that of a normal pancreas. The study is published in Cancer Discovery, a journal of the American Association for Cancer Research. Co-senior authors Marina Pasca di Magliano, PhD, Maud T. Lane Professor of Surgical Immunology, and Timothy Frankel, MD, Maud T. Lane Professor of Surgical Oncology, are co-directors of the Rogel and Blondy Center for Pancreatic Cancer.
Leveraging Biological Similarities Could Help Humans and Dogs With Cancer
UF Health Cancer Institute
When man’s best friend develops cancer, veterinarians often use human medications to treat them, because dogs and humans share deep biological similarities. This creates an opportunity for both species to help each other, through comparative studies, said Elizabeth Maxwell, DVM, a surgical oncologist at the UF College of Veterinary Medicine.
Proton FLASH Therapy Protects Healthy Tissue by Preserving Gut Microbiome
The University of Kansas Cancer Center
Proton therapy, an advanced type of radiation treatment, can be used for some cancers when conventional radiation therapy poses a threat to surrounding tissue. While conventional radiation therapy delivers X-rays, or beams of photons, to the tumor and beyond it, proton therapy delivers beams of protons—positively charged atomic particles—that can be stopped at the tumor, with little to no "exit dose" passing through it. The result is less damage to the tissue surrounding the malignancy.
Study Proposes Reconsidering How Histone Deacetylase Inhibitors Work in Cancer Treatment
Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine
Researchers at Baylor College of Medicine and collaborating institutions are challenging the traditional understanding of how cancer drugs called histone deacetylase (HDAC) inhibitors function. The study, published in Signal Transduction and Targeted Therapy, highlights the importance of identifying genuine molecular targets of HDAC inhibitors as a next step to improve cancer treatment.
New CRISPR Technique Selectively Shreds Cancer Cells, Including 'Undruggable' Cancers
UCSF Helen Diller Family Comprehensive Cancer Center
UCSF researchers in collaboration with the Innovative Genomics Institute at UC Berkeley, Gladstone Institutes, and additional partners at the University of Utah and Utah State University, report that a creative new CRISPR-based approach can selectively destroy cells carrying a mutation in a tumor suppressor found in nearly half of all cancers.
Targeted Therapy Reduces Risk of Lung Cancer Recurrence in Rare Genetic Subtype
UCLA Jonsson Comprehensive Cancer Center
A new study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that the targeted cancer drug selpercatinib can significantly reduce the risk of lung cancer returning in patients with a rare genetic subtype of early-stage non-small cell lung cancer, potentially offering a new treatment option to help keep the disease from coming back after standard therapy. Overall, the treatment reduced the risk of cancer recurrence or death by 83 percent.
Machine Learning Model Improves Accuracy of Liquid Biopsy Results
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
A machine learning model developed by researchers at the Johns Hopkins Kimmel Cancer Center filters out the biological noise in liquid biopsy samples, helping clinicians better match therapies to their patients’ tumors. The research was published in Clinical Cancer Research and was funded in part by the National Institutes of Health.
Reprogrammed Glial Cells Might Tell Different Origin Story for Rare GI Cancers
The University of Arizona Cancer Center
University of Arizona Cancer Center Regents Professor Juanita L. Merchant, MD, PhD, and her research team have uncovered evidence suggesting that rare gastrointestinal neuroendocrine tumors may originate from reprogrammed glial cells rather than hormone-secreting endocrine cells — a finding that could shift understanding of how these cancers develop and open new treatment possibilities.
Novel Prostate Cancer Treatment Can Reduce Risk of Disease Progression by Half
Huntsman Cancer Institute at the University of Utah
A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer Institute and professor of internal medicine at the University of Utah, has found that a combination treatment in patients with metastatic castration-sensitive prostate cancer could prevent the disease from progressing in select patients.
Updated Colorectal Cancer Guidelines Endorse New Stool Tests
University of Virginia Cancer Center
With colorectal cancer a growing concern among younger people, the American Cancer Society (ACS) has endorsed two new types of stool tests to encourage people to get screened while also recommending a limited role for new blood tests many patients find appealing. The recommendations are an update to the ACS’s screening guidelines led by Andrew Wolf, MD, a cancer prevention expert at UVA Health.
Stopping Ewing Sarcoma Relapses Where They Start
University of Michigan Rogel Cancer Center
Two new drugs show promise in treating relapsed Ewing sarcoma, new studies from Rogel Cancer Center researchers report. Both drugs target the molecule responsible for RNA transcription that ultimately drives Ewing sarcoma tumor formation. The findings appear in Nature Medicine and Nature Communications.
Newly Discovered 'Chimeras' Influence Women's Health
University of Virginia Cancer Center
A research team led by University of Virginia faculty Hui Li, PhD, has identified a chimeric RNA called UBA1-CDK16 that is found only in women. This RNA, once thought to be a product of cancer, plays important roles in their blood cell development and in determining the severity of infectious diseases and autoimmune disorders. The findings could open the door to blood tests to help diagnose diseases or identify women at greatest risk for poor outcomes.
Researchers Create Renewable Cell Source
USC Norris Comprehensive Cancer Center
In a new study published in Cell, USC Stem Cell scientists and their collaborators have developed a renewable source of immune cells known as macrophages, which could advance immunotherapies for cancer and other diseases.
Expanding Horizons of CAR T-cell Treatment
The University of Kansas Cancer Center
It’s been nearly 10 years since the U.S. Food and Drug Administration approved the first chimeric antigen receptor T-cell (CAR-T) therapy to treat a type of leukemia. Today, there are seven FDA-approved CAR T-cell therapies, and the results have been revolutionary. Yet the majority of people eligible for CAR T therapy don't receive it. Researchers at KU Cancer Center are working to expand the use of CAR T, not only in terms of what malignancies this kind of therapy can treat, but also in expanding access for patients.
Scientists Uncover Genetic 'Shield' That Lowers Risk of Colorectal Cancer
Karmanos Cancer Institute, Wayne State University
Scientists from Karmanos Cancer Institute, Wayne State University, and institutions across the U.S., have published a paper on TGFBR1*6A, a naturally occurring genetic mutation, and how it influences a person’s risk of developing colorectal cancer. Boris Pasche, MD, PhD, FACP, president and CEO of Karmanos Cancer Institute, was the first to discover TGFBR1*6A as a cancer risk allele.
Evers: How Cancer Death Rates Hit 30-Year Low
UK Markey Cancer Center
In an op-ed published June 26 in the Lexington Herald Leader, B. Mark Evers, MD, FACS, highlights the role of clinical research in reducing cancer mortality in the United States by 34 percent since 1991. Dr. Evers is the director of UK Markey Cancer Center and a member of AACI's Board of Directors.
Winn Shares Story of Hope, Journey to Fox Chase
Fox Chase Cancer Center, Temple Health
AACI Immediate Past President Robert A. Winn, MD, joined Fox Chase Cancer Center as its new director last month. In an interview published on the Fox Chase website, he shared the experiences and people that shaped his career path — and his life. "I’m not so much a self-made man as I am a man made and created by the community that existed around me and lifted me up," said Dr. Winn.
Seven-Year-Old Patient is First to Receive Proton Therapy at Stanford Facility
Stanford Cancer Institute
Seventy years after Henry Kaplan pioneered the medical linear accelerator to treat a 2-year-old boy's retinoblastoma, Stanford Medicine treated its first patient—a 7-year-old boy with a rare, malignant brain tumor—at its new, ultracompact proton therapy facility, a watershed moment for Stanford's first-in-the-world technology.
Huntsman CEO Joins Cancer Symposium With HHS Secretary
Huntsman Cancer Institute at the University of Utah
During a City of Hope Comprehensive Cancer Center symposium, Huntsman Cancer Institute CEO Bradley Cairns, PhD, was among top cancer center leaders who met with U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr., to discuss emerging opportunities to advance cancer research and care.
New MRI-LINAC Allows for Better Precision in Radiation Treatments
University of New Mexico Comprehensive Cancer Center
A newly-installed MRI-linear accelerator (MRI-LINAC) at UNM Comprehensive Cancer Center (UNMCCC) combines the clarity of magnetic resonance imaging with targeted radiation therapy, potentially saving patients from multiple appointments and CT scans. David Lee, MD, PhD, is UNMCCC's medical director of Radiation Oncology.
Groundbreaking for the Future Mount Sinai Tisch Cancer Hospital
Mount Sinai Tisch Cancer Center
Pictured, left to right: Drs. Brendan G. Carr and Merryl H. Tisch, and James S. Tisch
A ceremonial groundbreaking for the new Mount Sinai Tisch Cancer Hospital took place on June 1. The transformational support from visionary philanthropic leaders James S. Tisch and Merryl H. Tisch, EdD, has brought this milestone project to life.
Redefining Cancer Survivorship
Fred Hutch Cancer Center
There are 18 million cancer survivors in the United States, thanks to advances in care and treatment. Cancers that used to be death sentences are now treatable, but the effects of chemotherapy, radiation and surgery can last long after treatment ends. An emerging field of cancer care called survivorship focuses on helping people manage the short- and long-term or late effects of cancer treatment. A new Fred Hutch podcast, From Bench to Bedside and Beyond, dives deep into what it means—physically, emotionally and spiritually—to survive cancer.
Cedars-Sinai Launches New Cayton BRCA Center
Cedars-Sinai Cancer
Supported by a $30 million gift from the Cayton Goldrich Family Foundation, the Cedars-Sinai Cayton BRCA Center will open in early July. "This center will provide every relevant service: comprehensive risk assessment, state-of-the-art surveillance, prevention strategies, clinical trials, and access to the latest scientific discoveries," said Farin Amersi, MD, a surgical oncologist who treats patients with BRCA mutations. "More importantly, it will create a true home for patients and families facing hereditary cancer risk."
Conversations in Cancer: Cell Therapy
Duke Cancer Institute
At Duke Cancer Institute (DCI), researchers are making cell therapies safer and more effective and investigating whether specially engineered cell therapies can be used to treat solid tumors like lung cancer. A new video for DCI's ongoing Conversations in Cancer series explains how cell therapies work and what the future may hold.
Karmanos Cancer Institute Reaches Historic Growth Milestone
Karmanos Cancer Institute, Wayne State University
Karmanos Cancer Institute celebrated the continued success of a multi-year growth strategy with a major milestone in Fiscal Year 2025, treating 15,754 new cancer cases, the most in its history. The achievement reflects a more than 47-percent increase in new cases compared to the 10,670 new cases in 2020, representing one of the most significant sustained growth trajectories among National Cancer Institute-Designated Comprehensive Cancer Centers nationwide.
Cancer Center Jobs
Houston Methodist Dr. Mary and Ron Neal Cancer Center
Read moreHollings Cancer Center, Medical University of South Carolina
Read moreHuntsman Cancer Institute at the University of Utah
Read moreUpstate Cancer Center, SUNY Upstate Medical University
Read moreUNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Read moreMeeting Announcements
AACI/SIRUM Webinar: Leveraging Surplus Medicine for Good
Cancer Center Community Impact Forum
The Cancer Center Community Impact Forum (CCCIF) is a national annual meeting of NCI Designated Cancer Center professionals and professionals at cancer centers working towards designation who are dedicated to advancing community-engaged cancer control. The meeting is hosted by the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium.
2026 AACI Leadership Development Workshop
The 2026 AACI Leadership Development Workshop will be held in conjunction with the 2026 AACI/CCAF Annual Meeting.
This event convenes emerging leaders for didactic and experiential leadership development sessions. An offshoot of Dr. Caryn Lerman’s AACI presidential initiative, the workshop aims to enhance the oncology leadership pipeline with top talent.
Support Opportunities
2026 Impact Summit
The 2026 Impact Summit will be held in conjunction with the 2026 AACI/CCAF Annual Meeting.
Co-hosted by AACI and the Cancer Center Network, the Impact Summit brings together cancer center leaders, researchers, and other stakeholders for a dynamic one-day event focused on strengthening the future of cancer center leadership and workforce development.
Support Opportunities
2026 New Cancer Center Directors Meeting
The 2026 New Cancer Center Directors Meeting will be held in conjunction with the 2026 AACI/CCAF Annual Meeting. Participation in this meeting is by invitation only.
2026 AACI/CCAF Annual Meeting
The 3-day AACI/CCAF annual meeting offers AACI members the opportunity to network with cancer center colleagues, national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges.
Support Opportunities
Save the Date: 2027 AACI/AACR Hill Day
Save the date for the 2027 AACI/AACR Hill Day. More information to come.
Save the Date: 19th Annual AACI CRI Meeting
Save the date for the 19th Annual AACI Clinical Research Innovation (CRI) Meeting, June 28-30, 2027, at the Loews Chicago O'Hare Hotel in Rosemont, IL.